H.R. 1561
ALERT Communities Act
Sponsor: Jasmine Crockett · 1 cosponsor
Follow this bill
Official summary
Written by the Congressional Research Service.
Advancing Lifesaving Efforts with Rapid Test strips for Communities Act or the ALERT Communities Act
This bill establishes programs and requirements to advance the development and usage of test strips that detect the presence of certain hazardous drugs (e.g., fentanyl, xylazine).
Currently, the Substance Abuse and Mental Health Services Administration provides grants to government entities to train and provide authorized equipment to first responders and other relevant personnel for emergency treatment of opioid overdoses. The bill expands these grants to include rapid response test strips for detecting the presence of fentanyl, xylazine, and other synthetic opioids or emerging substances in people or within other drugs.
Additionally, the bill requires the Department of Health and Human Services (HHS) to publish guidance and standards for test strip manufacturers to support the development, evaluation, and authorization of test strips.
Also, HHS must conduct a study and report to Congress on how the availability and usage of test strips and similar equipment impacts the frequency of overdoses and participation in substance use disorder treatment.
Text of the bill
The Secretary of Health and Human Services, in consultation with the Director of the National Institutes of Health, the Director of the Office of National Drug Control Policy, the Commissioner of Food and Drugs, and the Administrator of the Drug Enforcement Administration, shall develop and make publicly available research and marketing frameworks for developing, improving, and evaluating test strip technology for detecting fentanyl and other dangerous substances. Such frameworks shall—
(1) include standards and guidance for manufacturers seeking to develop and test new test strip technology;
(2) emphasize bringing new test strip technology intended for testing human specimens in clinical settings to support on-site clinical decision-making; and
(3) include guidance on available authorization pathways for test strips described in paragraphs (1) and (2).